| Literature DB >> 35068877 |
Long-Sheng Lu1, Yen-Wen Wu2, Joseph Tung-Chieh Chang3, Wei-Ting Chang4, Ting-Hsing Chao5, Helen Hai-Wen Chen6, Yu-Jen Chen7, Kai-Hung Cheng8, Wen-Lin Hsu9, Chung-Lieh Hung10, Sung-Hsin Kuo11, Ji-An Liang12, Hung-Ju Lin13, Ping-Yen Liu14, Wen-Shan Liu15, Yen-Wen Liu14, Pei-Wei Shueng16, Chao-Yung Wang17, Charles Jia-Yin Hou18, Jeng-Fong Chiou1.
Abstract
Advances in cancer management have significantly improved survival in patients with cancers. Cardiovascular complications of cancer treatment are becoming significant competing causes of death in these patients. Radiotherapy is an indispensable component of cancer treatment, and irradiation of the heart and vasculature during cancer radiotherapy is now recognized as a new risk factor for cardiovascular diseases. It is important to involve multidisciplinary expertise and provide practical recommendations to promote awareness, recognize risks, and provide adequate interventions without jeopardizing cancer control. In this consensus paper, experts from the Taiwan Society for Therapeutic Radiology and Oncology and Taiwan Society of Cardiology provide a focused update on the clinical practice for risk stratification and management of radiation-induced cardiovascular disease (RICVD). We believe that implementing RICVD care under a collaborative cardio-oncology program will significantly improve cancer treatment outcomes and will facilitate high quality clinical investigations.Entities:
Keywords: Cancer survivorship; Cardio-oncology; Cardiosparing radiotherapy; Radiation-induced cardiovascular diseases
Year: 2022 PMID： 35068877 PMCID： PMC8743478 DOI： 10.6515/ACS.202201_38(1).20211122A
Source DB: PubMed Journal: Acta Cardiol Sin ISSN： 1011-6842 Impact factor: 2.672